BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
©The Author(s) 2024.
World J Gastroenterol. Mar 7, 2024; 30(9): 1108-1120
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1108
Table 3 Treatment patterns of chronic erosive gastritis, n (%)
Variable
n = 3563
Variable
n = 3563
Treatment patterns
Only lifestyle instructions368 (10.3)
Drug combinationsDrug by category
MPA + PPI1126 (31.6)MPA2380 (66.8)
MPA392 (11.0)PPI2489 (69.9)
PPI325 (9.1)Anti-Hp404 (11.3)
MPA + PPI + PD302 (8.5)H2RA23 (0.6)
PPI + anti-Hp161 (4.5)PD608 (17.1)
MPA + PPI + anti-Hp151 (4.2)TCM250 (7.0)
MPA + PD92 (2.6)Others260 (7.3)
MPA + PPI + TCM65 (1.8)
PPI + PD51 (1.4)
PPI + TCM42 (1.2)
Others488 (13.7)

  • Citation: Yang YY, Li KM, Xu GF, Wang CD, Xiong H, Wang XZ, Wang CH, Zhang BY, Jiang HX, Sun J, Xu Y, Zhang LJ, Zheng HX, Xing XB, Wang LJ, Zuo XL, Ding SG, Lin R, Chen CX, Wang XW, Li JN. Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China. World J Gastroenterol 2024; 30(9): 1108-1120
  • URL: https://www.wjgnet.com/1007-9327/full/v30/i9/1108.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v30.i9.1108

Write to the Help Desk